Category Research

LEAP

LEAP Boosts Digital Lab Transformation with Key Executive Appointment in Clinical Diagnostics

LEAP Boosts Digital Lab Transformation with Key Executive Appointment in Clinical Diagnostics LEAP Consulting Group, a renowned boutique digital consultancy specializing in guiding national clinical diagnostic laboratories through complex, multi-phase digital transformations, has announced a strategic executive appointment that marks…

Read MoreLEAP Boosts Digital Lab Transformation with Key Executive Appointment in Clinical Diagnostics
Pfizer

Pfizer’s Sasanlimab Boosts Event-Free Survival in High-Risk NMIBC

Pfizer’s Sasanlimab Boosts Event-Free Survival in High-Risk NMIBC Pfizer Inc. (NYSE: PFE) announced today significant findings from its pivotal Phase 3 CREST trial evaluating sasanlimab, an investigational anti-PD-1 monoclonal antibody, in combination with the standard of care (SOC) Bacillus Calmette-Guérin…

Read MorePfizer’s Sasanlimab Boosts Event-Free Survival in High-Risk NMIBC

UGN-102 Trials Show No Impact on Function, Symptoms, or QoL in LG-IR-NMIBC Patients

UGN-102 Trials Show No Impact on Function, Symptoms, or QoL in LG-IR-NMIBC Patients UroGen Pharma Ltd. (Nasdaq: URGN), a biotechnology company focused on developing and commercializing innovative treatments for urothelial and specialty cancers, announced new data supporting its investigational intravesical…

Read MoreUGN-102 Trials Show No Impact on Function, Symptoms, or QoL in LG-IR-NMIBC Patients
CytoAgents

CytoAgents Completes Cohort 1 Dose-Escalation in Phase 1B Clinical Trial for Cytokine Release Syndrome Research

CytoAgents Completes Cohort 1 Dose-Escalation in Phase 1B Clinical Trial for Cytokine Release Syndrome Research CytoAgents Inc., a clinical-stage biotechnology company at the forefront of developing therapies for immune-mediated disorders, has announced a significant milestone in its ongoing Phase 1b/2a…

Read MoreCytoAgents Completes Cohort 1 Dose-Escalation in Phase 1B Clinical Trial for Cytokine Release Syndrome Research
Debiopharm

Debiopharm and Oncodesign Services Partner to Advance Radiopharmaceuticals in Preclinical Research

Debiopharm and Oncodesign Services Partner to Advance Radiopharmaceuticals in Preclinical Research Debiopharm Research & Manufacturing S.A. (Debiopharm), a privately held, Swiss-based global biopharmaceutical company committed to advancing the treatment landscape for cancer and infectious diseases, has announced a strategic licensing…

Read MoreDebiopharm and Oncodesign Services Partner to Advance Radiopharmaceuticals in Preclinical Research
Novocure

Novocure to Present Late-Breaking Phase 3 PANOVA-3 Data for TTFields in Pancreatic Cancer at ASCO 2025

Novocure to Present Late-Breaking Phase 3 PANOVA-3 Data for TTFields in Pancreatic Cancer at ASCO 2025 Novocure, a global leader in innovative cancer treatments, has announced that it will present additional data from its pivotal Phase 3 PANOVA-3 trial of…

Read MoreNovocure to Present Late-Breaking Phase 3 PANOVA-3 Data for TTFields in Pancreatic Cancer at ASCO 2025
Biotech

Metro International Biotech Begins Phase 1a Trial of NAD Booster MIB-725

Metro International Biotech Begins Phase 1a Trial of NAD Booster MIB-725 Metro International Biotech, LLC (MetroBiotech), a pioneering company in the development of next-generation therapies for age-associated diseases, has officially launched its first-in-human clinical trial for MIB-725, a novel investigational…

Read MoreMetro International Biotech Begins Phase 1a Trial of NAD Booster MIB-725
Glycomine

Glycomine Raises $115M Series C to Advance GLM101 into Phase 2b Trial for PMM2-CDG

Glycomine Raises $115M Series C to Advance GLM101 into Phase 2b Trial for PMM2-CDG Glycomine, Inc., a clinical-stage biotechnology company dedicated to developing life-changing therapies for patients suffering from orphan and underserved diseases, has announced the successful closure of a…

Read MoreGlycomine Raises $115M Series C to Advance GLM101 into Phase 2b Trial for PMM2-CDG